- Home
- GALT vs ZNTL Comparison
GALT vs ZNTL Comparison
Compare GALT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | ZNTL |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 468.9M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GALT | ZNTL |
|---|---|---|
| Price | $2.46 | $5.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.50 | $6.60 |
| AVG Volume (30 Days) | 307.8K | ★ 3.6M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $1.13 |
| 52 Week High | $7.13 | $6.95 |
Technical Indicators
Market Signals| Indicator | GALT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 67.76 |
| Support Level | $2.13 | $1.31 |
| Resistance Level | $3.32 | N/A |
| Average True Range (ATR) | 0.22 | 0.63 |
| MACD | -0.02 | 0.36 |
| Stochastic Oscillator | 33.33 | 64.04 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.